CVS Health will not cover Gilead's Yeztugo, generic name lenacapavir (LEN), citing "clinical, financial, and regulatory ...

CVS stores are scheduled to open at former Rite Aid locations in Oregon between August and the end of September. Here are the ...

The store at 1515 W. State St. near downtown was planned to be sold to CVS Pharmacy as part of Rite Aid’s bankruptcy ...

Whistleblower Sarah Behnke's lawsuit leads to a $290 million judgment against CVS Caremark for overcharging Medicare on ...

A federal judge ordered CVS Health's pharmacy benefit manager unit to pay $289.9 million in damages and penalties after it ...

CVS Health , which runs the largest U.S. pharmacy benefit manager, will not add Gilead Sciences' new HIV prevention drug to ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

The owner of the U.S.' largest pharmacy benefit manager is declining to cover Gilead Sciences’ long-acting HIV prevention ...

CVS Health (CVS) stock in focus as its pharmacy benefit manager CVS Caremark faces $289.9M in damages and penalties for ...

The Gilead HIV prevention shot , called Yevtugo, is highly effective, but its list price is $28, 218 a year in the U.S.

CVS Health (CVS) won't include Gilead's (GILD) new HIV drug Yeztugo in its commercial healthcare plans, due to clinical, regulatory and financial factors. Read more here.

CVS Health Corp., parent of Hartford-based Aetna Inc., said Friday it has agreed to issue and sell $4 billion in notes.